Published in BMC Cancer on February 04, 2014
Racial Disparities in Breast Cancer Diagnosis and Treatment by Hormone Receptor and HER2 Status. Cancer Epidemiol Biomarkers Prev (2015) 1.43
Resistin and interleukin-6 exhibit racially-disparate expression in breast cancer patients, display molecular association and promote growth and aggressiveness of tumor cells through STAT3 activation. Oncotarget (2015) 0.96
Trends of triple negative breast cancer research (2007-2015): A bibliometric study. Medicine (Baltimore) (2016) 0.81
Race-associated biological differences among Luminal A breast tumors. Breast Cancer Res Treat (2015) 0.81
Racial disparity in metabolic regulation of cancer. Front Biosci (Landmark Ed) (2017) 0.76
Outcome Disparities in African American Compared with European American Women with ER+HER2- Tumors Treated within an Equal-Access Health Care System. Ethn Dis (2016) 0.76
Mammography Adherence in African-American Women: Results of a Randomized Controlled Trial. Ann Behav Med (2016) 0.75
African-American Women's Perceptions and Experiences About Breastfeeding. Front Public Health (2015) 0.75
Triple negative breast cancer in North of Morocco: clinicopathologic and prognostic features. BMC Womens Health (2016) 0.75
Breast cancer subtype of French women is not influenced by socioeconomic status: A population-based-study. PLoS One (2017) 0.75
Differentially expressed miRNAs in triple negative breast cancer between African-American and non-Hispanic white women. Oncotarget (2016) 0.75
Biologic roles of estrogen receptor-β and insulin-like growth factor-2 in triple-negative breast cancer. Biomed Res Int (2015) 0.75
Lower frequency of TLR9 variant associated with protection from breast cancer among African Americans. PLoS One (2017) 0.75
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology (1991) 30.87
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA (2006) 24.01
Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer (1957) 21.59
Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res (2007) 16.79
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol (2010) 14.41
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst (2009) 10.91
Epidemiology of basal-like breast cancer. Breast Cancer Res Treat (2007) 7.08
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst (2010) 4.54
Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res (2008) 3.39
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res (2010) 3.04
Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res (2009) 2.59
Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer. Cancer (2008) 2.56
Breast cancer in African-American women. Oncologist (2005) 1.98
Factors influencing inclusion of patients with malignancies in clinical trials. Cancer (2006) 1.76
Understanding and treating triple-negative breast cancer. Oncology (Williston Park) (2008) 1.73
Differences in the tumor microenvironment between African-American and European-American breast cancer patients. PLoS One (2009) 1.72
Widening disparity in survival between white and African-American patients with breast carcinoma treated in the U. S. Department of Defense Healthcare system. Cancer (2003) 1.66
Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev (2008) 1.53
Reproductive factors and risk of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among women 20-44 years of age. Breast Cancer Res Treat (2012) 1.30
Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat (2012) 1.27
Higher parity and shorter breastfeeding duration: association with triple-negative phenotype of breast cancer. Cancer (2010) 1.18
Smoking and alcohol consumption in relation to risk of triple-negative breast cancer in a cohort of postmenopausal women. Cancer Causes Control (2011) 1.15
Identification of differentially expressed genes in breast tumors from African American compared with Caucasian women. Cancer (2011) 1.14
Differential endothelial cell gene expression by African Americans versus Caucasian Americans: a possible contribution to health disparity in vascular disease and cancer. BMC Med (2011) 1.11
Genetic susceptibility loci for subtypes of breast cancer in an African American population. Cancer Epidemiol Biomarkers Prev (2012) 1.10
Differential gene expression between African American and European American colorectal cancer patients. PLoS One (2012) 1.09
Tea and coffee intake in relation to risk of breast cancer in the Black Women's Health Study. Cancer Causes Control (2010) 1.03
The Northwest Lipid Research Clinic Fat Intake Scale: validation and utility. Am J Public Health (1997) 1.02
Consumption of coffee, but not black tea, is associated with decreased risk of premenopausal breast cancer. J Nutr (2006) 0.98
Genome-wide copy number alterations in subtypes of invasive breast cancers in young white and African American women. Breast Cancer Res Treat (2011) 0.98
Racial differences in outcomes of triple-negative breast cancer. Breast Cancer Res Treat (2013) 0.93
The Clinical Breast Care Project: an important resource in investigating environmental and genetic contributions to breast cancer in African American women. Cell Tissue Bank (2007) 0.84
The second human beta B2-crystallin gene is a pseudogene. Exp Eye Res (1992) 0.83
Calorie restriction extends Saccharomyces cerevisiae lifespan by increasing respiration. Nature (2002) 8.45
Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J Clin Oncol (2011) 2.78
Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol (2005) 2.43
Assessing semantic similarity measures for the characterization of human regulatory pathways. Bioinformatics (2006) 2.29
Circulating MMP2 and MMP9 in breast cancer -- potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories. Int J Cancer (2006) 2.00
The genomic heritage of lymph node metastases: implications for clinical management of patients with breast cancer. Ann Surg Oncol (2008) 1.87
Genomic alterations associated with early stages of breast tumor metastasis. Ann Surg Oncol (2008) 1.61
Standard versus pH-adjusted and lidocaine supplemented radiocolloid for patients undergoing sentinel-lymph-node mapping and biopsy for early breast cancer (PASSION-P trial): a double-blind, randomised controlled trial. Lancet Oncol (2009) 1.57
Prospective trial of voice outcomes after thyroidectomy: evaluation of patient-reported and clinician-determined voice assessments in identifying postthyroidectomy dysphonia. Surgery (2008) 1.53
Correlation of levels and patterns of genomic instability with histological grading of DCIS. Ann Surg Oncol (2007) 1.47
The impact of recurrent laryngeal neuromonitoring on multi-dimensional voice outcomes following thyroid surgery. J Surg Oncol (2011) 1.46
A gene expression signature that defines breast cancer metastases. Clin Exp Metastasis (2008) 1.34
Functional identity of genes detectable in expression profiling assays following globin mRNA reduction of peripheral blood samples. Clin Biochem (2007) 1.25
A prospective evaluation of patients undergoing surgery for the palliation of an advanced malignancy. Ann Surg Oncol (2002) 1.25
High-throughput loss of heterozygosity mapping in 26 commonly deleted regions in breast cancer. Cancer Epidemiol Biomarkers Prev (2003) 1.20
Effect of ASCO/CAP guidelines for determining ER status on molecular subtype. Ann Surg Oncol (2012) 1.14
Identification of differentially expressed genes in breast tumors from African American compared with Caucasian women. Cancer (2011) 1.14
Development of a Bayesian classifier for breast cancer risk stratification: a feasibility study. Eplasty (2010) 1.14
Outer breast quadrants demonstrate increased levels of genomic instability. Ann Surg Oncol (2004) 1.08
Evaluation of the CD107 cytotoxicity assay for the detection of cytolytic CD8+ cells recognizing HER2/neu vaccine peptides. Breast Cancer Res Treat (2005) 1.06
The use of rapid parathyroid hormone assay in predicting postoperative hypocalcemia after total or completion thyroidectomy. Thyroid (2006) 1.06
Proteomics of breast carcinoma. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 1.04
Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer. Ann Surg Oncol (2006) 1.03
Breast cancer in the personal genomics era. Curr Genomics (2010) 1.02
Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex technology. Oncol Rep (2007) 1.02
Electrical impedance scanning for the early detection of breast cancer in young women: preliminary results of a multicenter prospective clinical trial. J Clin Oncol (2005) 1.00
Core biopsy diagnosis of ductal carcinoma in situ: an indication for sentinel lymph node biopsy. Curr Surg (2005) 1.00
Lung cancer survival among black and white patients in an equal access health system. Cancer Epidemiol Biomarkers Prev (2012) 0.99
DW4TR: A Data Warehouse for Translational Research. J Biomed Inform (2011) 0.99
Performance of whole-genome amplified DNA isolated from serum and plasma on high-density single nucleotide polymorphism arrays. J Mol Diagn (2008) 0.98
Genomic instability in histologically normal breast tissues: implications for carcinogenesis. Lancet Oncol (2004) 0.98
Detecting outlier microarray arrays by correlation and percentage of outliers spots. Cancer Inform (2007) 0.98
Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes. Breast Cancer Res (2012) 0.96
Correlations between serum monocyte chemotactic protein-1 levels, clinical prognostic factors, and HER-2/neu vaccine-related immunity in breast cancer patients. Clin Cancer Res (2006) 0.95
The evaluation of casualties from Operation Iraqi Freedom on return to the continental United States from March to June 2003. J Am Coll Surg (2005) 0.95
HYOU1/Orp150 expression in breast cancer. Med Sci Monit (2007) 0.93
Plasma concentration and activity of matrix metalloproteinase 2 and 9 in patients with breast disease, breast cancer and at risk of developing breast cancer. Cancer Lett (2006) 0.93
Prospective study of electrical impedance scanning for identifying young women at risk for breast cancer. Breast Cancer Res Treat (2006) 0.93
Socioeconomic disparities and breast cancer hormone receptor status. Cancer Causes Control (2012) 0.92
Race and colon cancer survival in an equal-access health care system. Cancer Epidemiol Biomarkers Prev (2013) 0.92
Intensive cardiovascular risk reduction induces sustainable changes in expression of genes and pathways important to vascular function. Circ Cardiovasc Genet (2014) 0.91
Autologous pancreatic islet transplantation for severe trauma. N Engl J Med (2010) 0.90
Does breast tumor heterogeneity necessitate further immunohistochemical staining on surgical specimens? J Am Coll Surg (2012) 0.89
Amplification of HER2 is a marker for global genomic instability. BMC Cancer (2008) 0.88
Electrical impedance scanning as a new breast cancer risk stratification tool for young women. J Surg Oncol (2008) 0.88
Genomic patterns of allelic imbalance in disease free tissue adjacent to primary breast carcinomas. Breast Cancer Res Treat (2004) 0.88
Global search for chromosomal abnormalities in infiltrating ductal carcinoma of the breast using array-comparative genomic hybridization. Cancer Genet Cytogenet (2004) 0.88
Preoperative thyroid ultrasound in all patients undergoing parathyroidectomy? J Surg Res (2008) 0.87
Socioeconomic disparities in colorectal cancer mortality in the United States, 1990-2007. J Community Health (2014) 0.87
Leukocyte DNA as surrogate for the evaluation of imprinted Loci methylation in mammary tissue DNA. PLoS One (2013) 0.87
Laser microdissection for gene expression profiling. Methods Mol Biol (2011) 0.86
Correlation of levels and patterns of genomic instability with histological grading of invasive breast tumors. Breast Cancer Res Treat (2007) 0.86
A Bayesian derived network of breast pathology co-occurrence. J Biomed Inform (2008) 0.86
Breast cancer screening compliance among young women in a free access healthcare system. J Surg Oncol (2008) 0.85
Analysis of naïve and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine. Cancer Immunol Immunother (2006) 0.85
Thyroid cancer yield in patients with Graves' disease selected for surgery on the basis of cold scintiscan defects. Thyroid (2002) 0.85
Evaluation of BRCA1 mutations in an unselected patient population with triple-negative breast cancer. Breast Cancer Res Treat (2012) 0.85
Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine. Breast Cancer Res Treat (2006) 0.85
The Clinical Breast Care Project: an important resource in investigating environmental and genetic contributions to breast cancer in African American women. Cell Tissue Bank (2007) 0.84
Vaccination with a HER2/neu peptide induces intra- and inter-antigenic epitope spreading in patients with early stage breast cancer. Surgery (2006) 0.84
Chromosomal alterations associated with the transition from in situ to invasive breast cancer. Ann Surg Oncol (2008) 0.84
Differential gene expression in primary breast tumors associated with lymph node metastasis. Int J Breast Cancer (2011) 0.83
Colon cancer treatment: are there racial disparities in an equal-access healthcare system? Dis Colon Rectum (2014) 0.83
FH535 inhibited migration and growth of breast cancer cells. PLoS One (2012) 0.83
Allelic imbalance in primary breast carcinomas and metastatic tumors of the axillary lymph nodes. Mol Cancer Res (2005) 0.83
Pain ratings by patients and their providers of radionucleotide injection for breast cancer lymphatic mapping. Pain Med (2012) 0.83
Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial. Cancer (2006) 0.83
Racial variation in breast cancer treatment among Department of Defense beneficiaries. Cancer (2011) 0.83
Molecular changes in primary breast tumors and the Nottingham Histologic Score. Pathol Oncol Res (2009) 0.83
Colon sentinel lymph node mapping: practical surgical applications. J Am Coll Surg (2005) 0.82
Exploring human plasma proteome strategies: high efficiency in-solution digestion protocol for multi-dimensional protein identification technology. J Chromatogr A (2005) 0.82
Doing more: trends in breast cancer surgery, 2005 to 2011. Am Surg (2015) 0.81
Role of cytochrome P450 genes in breast cancer etiology and treatment: effects on estrogen biosynthesis, metabolism, and response to endocrine therapy. Cancer Causes Control (2015) 0.81
Timing of critical genetic changes in human breast disease. Ann Surg Oncol (2005) 0.81
Factors associated with the incompliance with mammogram screening among individuals with a family history of breast cancer or ovarian cancer. Breast Cancer Res Treat (2006) 0.81
Biomedical informatics: development of a comprehensive data warehouse for clinical and genomic breast cancer research. Pharmacogenomics (2004) 0.80
Relationships between the ABO blood group SNP rs505922 and breast cancer phenotypes: a genotype-phenotype correlation study. BMC Med Genet (2012) 0.80
Electrical impedance scanning of thyroid nodules before thyroid surgery: a prospective study. Ann Surg Oncol (2005) 0.80
PSPHL and breast cancer in African American women: causative gene or population stratification? BMC Genet (2014) 0.80
Prolactin-Stat5 signaling in breast cancer is potently disrupted by acidosis within the tumor microenvironment. Breast Cancer Res (2013) 0.80
Surveillance mammography among female Department of Defense beneficiaries: a study by race and ethnicity. Cancer (2013) 0.80
Molecular response of the axillary lymph node microenvironment to metastatic colonization. Clin Exp Metastasis (2014) 0.80
The effect of changing gamma count threshold on sentinel lymph node accuracy. Curr Surg (2005) 0.79
Caring for the wounded in Iraq--a photo essay. N Engl J Med (2004) 0.79
Molecular alterations associated with breast cancer mortality. PLoS One (2012) 0.79
Analysis of metabolic and regulatory pathways through Gene Ontology-derived semantic similarity measures. AMIA Annu Symp Proc (2005) 0.79
Racial variation in tumor stage at diagnosis among Department of Defense beneficiaries. Cancer (2011) 0.79
Racial/ethnic differences in breast cancer survival by inflammatory status and hormonal receptor status: an analysis of the Surveillance, Epidemiology, and End Results data. Cancer Causes Control (2014) 0.79
Genomic instability in the breast microenvironment? A critical evaluation of the evidence. Expert Rev Mol Diagn (2009) 0.79
Label-free semiquantitative peptide feature profiling of human breast cancer and breast disease sera via two-dimensional liquid chromatography-mass spectrometry. Mol Cell Proteomics (2006) 0.78
Prospective trial evaluating electrical impedance scanning of thyroid nodules before thyroidectomy: final results. Ann Surg (2008) 0.78
Breast reconstruction after mastectomy among Department of Defense beneficiaries by race. Cancer (2014) 0.78
Survival among Black and White patients with renal cell carcinoma in an equal-access health care system. Cancer Causes Control (2015) 0.78
NSQIP Analysis: Increased Immediate Reconstruction in the Treatment of Breast Cancer. Am Surg (2016) 0.78
Environmental chemicals and breast cancer risk--a structural chemistry perspective. Curr Med Chem (2008) 0.78
Genomic instability and the development of metastatic lymph node tumors. Ann Surg Oncol (2007) 0.78
A Prognostic Model to Predict Mortality among Non-Small-Cell Lung Cancer Patients in the U.S. Military Health System. J Thorac Oncol (2015) 0.77